Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV - Patient-Reported Outcomes From the CAPELLA Trial Align With the Demonstrated Safety and Tolerability Profile of Lenacapavir - Analyses Show Oral
![Immagine News](/media/0icnkhat/cat-1.jpg?center=0.55476190476190479,0.25&mode=crop&width=722&height=442)
Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated HIV clinical care. The data were presented at the 12th International AIDS Society (IAS) Conference on HIV Science (IAS 2023), taking place July 23-26 in Brisbane, Australia.
For additional information, please refer to the following link: https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/twice-yearly-lenacapavir-demonstrates-sustained-impact-on-health-related-quality-of-life-in-people-with-hiv